Dirk Pleimes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dirk Pleimes has a total of 143 co-authors. Here are the top co-authors by number of shared publications:
- Frederik Barkhof
Amsterdam UMC, Location VUmc
6 shared publications - Xavier Montalban
Centro de Esclerosis Múltiple de Cataluña y Departamento de Neurología, Hospital Universitario Vall d’Hebron, 08035 Barcelona, España
6 shared publications - Corinna Asang
Myelo Therapeutics GmbH
5 shared publications Gilles Edan
5 shared publications- Radoslaw Wesolowski
Myelo Therapeutics GmbH
5 shared publications Rupert Sandbrink
5 shared publications
Latest Publications
- Open Access
- 7 August 2026
- Published by Taylor & Francis in International Journal of Radiation Biology
- Vol. 102 (12) , 1573-1584
Correlation of a four gene set with H-ARS severity in irradiated minipigs treated with Myelo001
The heightened risk of radiological and nuclear incidents due to global conflicts underscores the need for early diagnosis of the acute radiation syndrome (ARS) and its subcategory, the hematopoiet...
- 7 August 2026
- Published by Taylor & Francis in International Journal of Radiation Biology
- Vol. 102 (12) , 1573-1584
Open AccessCorrelation of a four gene set with H-ARS severity in irradiated minipigs treated with Myelo001
The heightened risk of radiological and nuclear incidents due to global conflicts underscores the need for early diagnosis of the acute radiation syndrome (ARS) and its subcategory, the hematopoiet...
- 26 May 2026
- Published by Taylor & Francis in International Journal of Radiation Biology
- Vol. 102 (9) , 1-16
Pharmacokinetics, pharmacodynamics, and radiomitigative efficacy of IEPA in a non-human primate model of acute radiation syndrome
The acute radiation syndrome (ARS) represents a significant public health threat following nuclear exposure, with limited available medical countermeasures (MCMs). Imidazolyl ethanamide pentandioic acid (IEPA), a novel orally bioavailable small molecule, has demonstrated radioprotective effects in rodent models earlier. This study continues the investigation of IEPA as a MCM in non-human primates (NHP), a recognized large animal model for ARS. Pharmacokinetic (PK) profiles and pharmacodynamic (PD) effects of IEPA were investigated in cynomolgus monkeys exposed to total-body irradiation (TBI) to assess its efficacy in reducing ARS-related mortality and mitigating radiation-induced myelosuppression (RIM). In addition to survival and clinical parameters, serum chemistry and bone marrow histology were analyzed. IEPA showed fast systemic absorption with linear, dose-dependent pharmacokinetics, a trend toward hematologic recovery, and improved survival outcomes in treated animals. For clinical chemistry and bone marrow histology, no significant changes were observed. These results indicate that IEPA has the potential to be further investigated as a MCM for ARS. To continue toward a clinical development path, the confirmation of the presented results with a study design adequately powered to assess a drug-mediated survival benefit is needed.
- 26 May 2026
- Published by Taylor & Francis in International Journal of Radiation Biology
- Vol. 102 (9) , 1-16
Pharmacokinetics, pharmacodynamics, and radiomitigative efficacy of IEPA in a non-human primate model of acute radiation syndrome
The acute radiation syndrome (ARS) represents a significant public health threat following nuclear exposure, with limited available medical countermeasures (MCMs). Imidazolyl ethanamide pentandioic acid (IEPA), a novel orally bioavailable small molecule, has demonstrated radioprotective effects in rodent models earlier. This study continues the investigation of IEPA as a MCM in non-human primates (NHP), a recognized large animal model for ARS. Pharmacokinetic (PK) profiles and pharmacodynamic (PD) effects of IEPA were investigated in cynomolgus monkeys exposed to total-body irradiation (TBI) to assess its efficacy in reducing ARS-related mortality and mitigating radiation-induced myelosuppression (RIM). In addition to survival and clinical parameters, serum chemistry and bone marrow histology were analyzed. IEPA showed fast systemic absorption with linear, dose-dependent pharmacokinetics, a trend toward hematologic recovery, and improved survival outcomes in treated animals. For clinical chemistry and bone marrow histology, no significant changes were observed. These results indicate that IEPA has the potential to be further investigated as a MCM for ARS. To continue toward a clinical development path, the confirmation of the presented results with a study design adequately powered to assess a drug-mediated survival benefit is needed.
- Open Access
- 20 November 2025
- Published by Taylor & Francis in International Journal of Radiation Biology
- Vol. 102 (2) , 97-104
Applicability of a four-gene set for H-ARS severity prediction in peripheral blood samples of irradiated minipigs
The fast diagnosis of the life-threatening acute radiation syndrome is crucial, as the early prediction of the hematological acute radiation syndrome (H-ARS) can save lives. Previously, we validated a four-gene set (FDXR, DDB2, POU2AF1, WNT3) for H-ARS severity prediction in non-human primates and leukemia patients. In this study, we aim to validate this gene set in minipigs as a surrogate model. 12 Göttingen minipigs, irradiated with 1.8 or 2.1 Gray (LD≈40/30), were examined. METREPOL H-ARS severity degrees were determined using sequential blood cell count changes over time after irradiation. For quantitative Real-Time-PCR (qRT-PCR), peripheral whole blood was withdrawn before and on days 1, 3, and 10 after irradiation. Normalization was performed using 18S rRNA and PUM1 as housekeeping genes (HKG). Differential gene expression (DGE) relative to the pre-irradiated samples was calculated. All minipigs developed a 2-4 H-ARS-severity degree. 18S rRNA revealed significantly (p = .0005) about two-fold higher variance of raw Ct-values than PUM1. DGE was calculated for all genes except WNT3 (undetectable in most animals). All genes revealed a slight up-regulation over time in most animals, but DGE > 2 regarding FDXR or DDB2 and concomitant downregulation of POU2AF1 (DGE < 0.5) as expected given the H-ARS severity degrees, was not observed. None of the animals revealed the expected DGE pattern corresponding to a moderate to high H-ARS-severity degree. Hence, the Göttingen minipig did not qualify as another validation model for our specific gene set, which does not argue against their validity for other purposes.
- 20 November 2025
- Published by Taylor & Francis in International Journal of Radiation Biology
- Vol. 102 (2) , 97-104
Open AccessApplicability of a four-gene set for H-ARS severity prediction in peripheral blood samples of irradiated minipigs
The fast diagnosis of the life-threatening acute radiation syndrome is crucial, as the early prediction of the hematological acute radiation syndrome (H-ARS) can save lives. Previously, we validated a four-gene set (FDXR, DDB2, POU2AF1, WNT3) for H-ARS severity prediction in non-human primates and leukemia patients. In this study, we aim to validate this gene set in minipigs as a surrogate model. 12 Göttingen minipigs, irradiated with 1.8 or 2.1 Gray (LD≈40/30), were examined. METREPOL H-ARS severity degrees were determined using sequential blood cell count changes over time after irradiation. For quantitative Real-Time-PCR (qRT-PCR), peripheral whole blood was withdrawn before and on days 1, 3, and 10 after irradiation. Normalization was performed using 18S rRNA and PUM1 as housekeeping genes (HKG). Differential gene expression (DGE) relative to the pre-irradiated samples was calculated. All minipigs developed a 2-4 H-ARS-severity degree. 18S rRNA revealed significantly (p = .0005) about two-fold higher variance of raw Ct-values than PUM1. DGE was calculated for all genes except WNT3 (undetectable in most animals). All genes revealed a slight up-regulation over time in most animals, but DGE > 2 regarding FDXR or DDB2 and concomitant downregulation of POU2AF1 (DGE < 0.5) as expected given the H-ARS severity degrees, was not observed. None of the animals revealed the expected DGE pattern corresponding to a moderate to high H-ARS-severity degree. Hence, the Göttingen minipig did not qualify as another validation model for our specific gene set, which does not argue against their validity for other purposes.
- 27 May 2025
- Published by Taylor & Francis in International Journal of Radiation Biology
- Vol. 101 (8) , 799-815
Imidazolyl ethanamide pentandioic acid promotes hematopoietic recovery following sublethal radiation in a murine model
Hematopoietic acute radiation syndrome (H-ARS) results from bone marrow (BM) damage, leading to depletion of myeloid and lymphoid cells and increasing infection, hemorrhage, and mortality risks. Imidazolyl ethanamide pentandioic acid (IEPA), an orally bioavailable molecule, alleviates chemotherapy-induced myelosuppression and may similarly mitigate H-ARS. This study examines whether IEPA, alone or with granulocyte-monocyte colony-stimulating factor (GM-CSF), promotes recovery of hematopoietic stem and progenitor cells (HSCs/HPCs) after sublethal total body irradiation (TBI). Mice received 5 Gy TBI followed by vehicle, IEPA (days 1-3), GM-CSF (days 1-5), or IEPA+GM-CSF. Recovery was assessed by body weight, blood counts, flow cytometry, clonogenic assays, BM megakaryocytes, and splenic CD34+ cells. IEPA increased body weight 2.5-fold by day 7, while IEPA+GM-CSF showed 2.5-fold and 3.3-fold increases on days 7 and 21, respectively. IEPA promoted recovery of HSCs/HPCs, multipotent progenitors (MPP2), myeloid and lymphoid progenitors, BM megakaryocytes, and splenic CD34+ cells. IEPA+GM-CSF improved in vitro self-renewal but offered no major in vivo advantage over IEPA alone, except for a 159-fold recovery in erythroid progenitors. All treatments reduced γ-H2AX expression in Lin- and HPCs on day 21, indicating less DNA damage. Our results reveal that IEPA attenuated radiation-induced DNA damage and improved recovery of HSCs/HPCs, myeloid as well as lymphoid progenitors, accompanied by increases in platelets in blood, megakaryocytes in BM and splenic CD34+ cells. IEPA shows promise as a radiation mitigator, with no significant benefit observed from adding GM-CSF.
- 27 May 2025
- Published by Taylor & Francis in International Journal of Radiation Biology
- Vol. 101 (8) , 799-815
Imidazolyl ethanamide pentandioic acid promotes hematopoietic recovery following sublethal radiation in a murine model
Hematopoietic acute radiation syndrome (H-ARS) results from bone marrow (BM) damage, leading to depletion of myeloid and lymphoid cells and increasing infection, hemorrhage, and mortality risks. Imidazolyl ethanamide pentandioic acid (IEPA), an orally bioavailable molecule, alleviates chemotherapy-induced myelosuppression and may similarly mitigate H-ARS. This study examines whether IEPA, alone or with granulocyte-monocyte colony-stimulating factor (GM-CSF), promotes recovery of hematopoietic stem and progenitor cells (HSCs/HPCs) after sublethal total body irradiation (TBI). Mice received 5 Gy TBI followed by vehicle, IEPA (days 1-3), GM-CSF (days 1-5), or IEPA+GM-CSF. Recovery was assessed by body weight, blood counts, flow cytometry, clonogenic assays, BM megakaryocytes, and splenic CD34+ cells. IEPA increased body weight 2.5-fold by day 7, while IEPA+GM-CSF showed 2.5-fold and 3.3-fold increases on days 7 and 21, respectively. IEPA promoted recovery of HSCs/HPCs, multipotent progenitors (MPP2), myeloid and lymphoid progenitors, BM megakaryocytes, and splenic CD34+ cells. IEPA+GM-CSF improved in vitro self-renewal but offered no major in vivo advantage over IEPA alone, except for a 159-fold recovery in erythroid progenitors. All treatments reduced γ-H2AX expression in Lin- and HPCs on day 21, indicating less DNA damage. Our results reveal that IEPA attenuated radiation-induced DNA damage and improved recovery of HSCs/HPCs, myeloid as well as lymphoid progenitors, accompanied by increases in platelets in blood, megakaryocytes in BM and splenic CD34+ cells. IEPA shows promise as a radiation mitigator, with no significant benefit observed from adding GM-CSF.
- Open Access
- 12 November 2024
- Published by Taylor & Francis in International Journal of Radiation Biology
- Vol. 101 (1) , 1-14
IEPA, a novel radiation countermeasure, alleviates acute radiation syndrome in rodents
Repurposing therapeutic agents with existing clinical data is a common strategy for developing radiation countermeasures. IEPA (imidazolyl ethanamide pentandioic acid) is an orally bioavailable small molecule pseudopeptide with myeloprotective properties, a good clinical safety profile, and stable chemical characteristics facilitating stockpiling. Here, we evaluated IEPA's radiomitigative efficacy in the hematopoietic subsyndrome of acute radiation syndrome (H-ARS) using total-body irradiation (TBI) models in C57BL/6J mice and WAG/RijCmcr rats, applying various posology schemes and introducing syringe feeding of the IEPA formulation in the pudding. Additionally, we assessed IEPA in the delayed effects of acute radiation exposure (DEARE) model after partial-body irradiation (PBI) in WAG/RijCmcr rats. Endpoints included survival, body weight, hematology, and pulmonary parameters, depending on the model. Results from mouse and rat TBI models demonstrated survival improvements with repeated IEPA dosing at 10 mg/kg, with the largest benefits observed in the bi-daily (BID) treatment over the 30-day ARS phase in female rats. Survival across PBI-DEARE subsyndromes was comparable between IEPA and vehicle groups, though IEPA improved pulmonary parameters in female rats during the lung-DEARE phase. Sex-related differences in response to irradiation and IEPA were noted, with females showing a survival advantage. IEPA treatment is compatible with Neulasta® (Pegfilgrastim; PEG-G-CSF); adequately powered studies are needed to confirm the trend toward improved survival over standard care alone. IEPA is a promising development candidate as a medical countermeasure against the effects of acute radiation syndrome. Further confirmatory studies in small and large animal models should validate the robustness and translatability of preliminary rodent data on IEPA's radiomitigative efficacy.
- 12 November 2024
- Published by Taylor & Francis in International Journal of Radiation Biology
- Vol. 101 (1) , 1-14
Open AccessIEPA, a novel radiation countermeasure, alleviates acute radiation syndrome in rodents
Repurposing therapeutic agents with existing clinical data is a common strategy for developing radiation countermeasures. IEPA (imidazolyl ethanamide pentandioic acid) is an orally bioavailable small molecule pseudopeptide with myeloprotective properties, a good clinical safety profile, and stable chemical characteristics facilitating stockpiling. Here, we evaluated IEPA's radiomitigative efficacy in the hematopoietic subsyndrome of acute radiation syndrome (H-ARS) using total-body irradiation (TBI) models in C57BL/6J mice and WAG/RijCmcr rats, applying various posology schemes and introducing syringe feeding of the IEPA formulation in the pudding. Additionally, we assessed IEPA in the delayed effects of acute radiation exposure (DEARE) model after partial-body irradiation (PBI) in WAG/RijCmcr rats. Endpoints included survival, body weight, hematology, and pulmonary parameters, depending on the model. Results from mouse and rat TBI models demonstrated survival improvements with repeated IEPA dosing at 10 mg/kg, with the largest benefits observed in the bi-daily (BID) treatment over the 30-day ARS phase in female rats. Survival across PBI-DEARE subsyndromes was comparable between IEPA and vehicle groups, though IEPA improved pulmonary parameters in female rats during the lung-DEARE phase. Sex-related differences in response to irradiation and IEPA were noted, with females showing a survival advantage. IEPA treatment is compatible with Neulasta® (Pegfilgrastim; PEG-G-CSF); adequately powered studies are needed to confirm the trend toward improved survival over standard care alone. IEPA is a promising development candidate as a medical countermeasure against the effects of acute radiation syndrome. Further confirmatory studies in small and large animal models should validate the robustness and translatability of preliminary rodent data on IEPA's radiomitigative efficacy.
- Open Access
- 21 May 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (10) , e034240
TPT‐004, a Next‐Generation Inhibitor of Tryptophan Hydroxylase, Ameliorates Pulmonary Arterial Hypertension in Rats
- 21 May 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (10) , e034240
Open AccessTPT‐004, a Next‐Generation Inhibitor of Tryptophan Hydroxylase, Ameliorates Pulmonary Arterial Hypertension in Rats
- 3 August 2022
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 65 (16) , 11126-11149
Structure-Based Design of Xanthine-Benzimidazole Derivatives as Novel and Potent Tryptophan Hydroxylase Inhibitors
Tryptophan hydroxylases catalyze the first and rate-limiting step in the synthesis of serotonin. Serotonin is a key neurotransmitter in the central nervous system and, in the periphery, functions as a local hormone with multiple physiological functions. Studies in genetically altered mouse models have shown that dysregulation of peripheral serotonin levels leads to metabolic, inflammatory, and fibrotic diseases. Overproduction of serotonin by tumor cells causes severe symptoms typical for the carcinoid syndrome, and tryptophan hydroxylase inhibitors are already in clinical use for patients suffering from this disease. Here, we describe a novel class of potent tryptophan hydroxylase inhibitors, characterized by spanning all active binding sites important for catalysis, specifically those of the cosubstrate pterin, the substrate tryptophan as well as directly chelating the catalytic iron ion. The inhibitors were designed to efficiently reduce serotonin in the periphery while not passing the blood-brain barrier, thus preserving serotonin levels in the brain.
- 3 August 2022
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 65 (16) , 11126-11149
Structure-Based Design of Xanthine-Benzimidazole Derivatives as Novel and Potent Tryptophan Hydroxylase Inhibitors
Tryptophan hydroxylases catalyze the first and rate-limiting step in the synthesis of serotonin. Serotonin is a key neurotransmitter in the central nervous system and, in the periphery, functions as a local hormone with multiple physiological functions. Studies in genetically altered mouse models have shown that dysregulation of peripheral serotonin levels leads to metabolic, inflammatory, and fibrotic diseases. Overproduction of serotonin by tumor cells causes severe symptoms typical for the carcinoid syndrome, and tryptophan hydroxylase inhibitors are already in clinical use for patients suffering from this disease. Here, we describe a novel class of potent tryptophan hydroxylase inhibitors, characterized by spanning all active binding sites important for catalysis, specifically those of the cosubstrate pterin, the substrate tryptophan as well as directly chelating the catalytic iron ion. The inhibitors were designed to efficiently reduce serotonin in the periphery while not passing the blood-brain barrier, thus preserving serotonin levels in the brain.
- Open Access
- 2 November 2021
- Published by Central Research Institute for Epidemiology in Journal of microbiology, epidemiology and immunobiology
- Vol. 98 (5) , 548-557
Evaluation of mutagenicity, genotoxicity and chronic toxicity of antiviral drug imidazolyl ethanamide pentandioic acid in in vitro and in vivo test systems
Introduction. The antiviral properties of imidazolyl ethanamide pentandioic acid (IPA), the active compound of the drug product, has been proven in various experimental models. However, the literature data on the toxicological properties of IPA are limited.Purpose. To evaluate mutagenic and genotoxic properties in in vitro and in vivo models, as well as to study the toxicity of IPA following chronic oral administration to rats and dogs.Materials and methods. Mutagenic and genotoxic properties of IPA were assessed using the Ames test, the test of chromosomal aberrations in human lymphocytes, and the micronucleus test in rats. The chronic toxicity of IPA was studied in Sprague Dawley rats and beagle dogs of both sexes, to which IPA was administered orally at doses of 30-300 mg/kg/day for 26 and 39 weeks, respectively.Results and discussion. In the Ames test, the addition of IPA up to the maximum dose (5000 mcg/plate) did not result in the increase in the number of revertant colonies. At a concentration of up to 5000 mcg/ml, IPA did not cause chromosomal aberrations in human leukocytes. At doses doses ≤ 2000 mg/kg, IPA did not increase the amount of micronuclei in the bone marrow of rats. In chronic experiments, animals tolerated the administration of IPA well: the dose without an observed effect (NOEL) for rats and dogs was 300 mg/kg/day.Conclusion. IPA did not show mutagenic and genotoxic properties in standard in vitro and in vivo tests. With chronic oral administration to rats and dogs, NOEL IPA equal to 300 mg/kg/day provided a systemic exposure that was 8-10 and 41-65 times higher than that in humans, respectively. The results obtained allow us to consider the safety profile of the prolonged use in humans as favorable.
- 2 November 2021
- Published by Central Research Institute for Epidemiology in Journal of microbiology, epidemiology and immunobiology
- Vol. 98 (5) , 548-557
Open AccessEvaluation of mutagenicity, genotoxicity and chronic toxicity of antiviral drug imidazolyl ethanamide pentandioic acid in in vitro and in vivo test systems
Introduction. The antiviral properties of imidazolyl ethanamide pentandioic acid (IPA), the active compound of the drug product, has been proven in various experimental models. However, the literature data on the toxicological properties of IPA are limited.Purpose. To evaluate mutagenic and genotoxic properties in in vitro and in vivo models, as well as to study the toxicity of IPA following chronic oral administration to rats and dogs.Materials and methods. Mutagenic and genotoxic properties of IPA were assessed using the Ames test, the test of chromosomal aberrations in human lymphocytes, and the micronucleus test in rats. The chronic toxicity of IPA was studied in Sprague Dawley rats and beagle dogs of both sexes, to which IPA was administered orally at doses of 30-300 mg/kg/day for 26 and 39 weeks, respectively.Results and discussion. In the Ames test, the addition of IPA up to the maximum dose (5000 mcg/plate) did not result in the increase in the number of revertant colonies. At a concentration of up to 5000 mcg/ml, IPA did not cause chromosomal aberrations in human leukocytes. At doses doses ≤ 2000 mg/kg, IPA did not increase the amount of micronuclei in the bone marrow of rats. In chronic experiments, animals tolerated the administration of IPA well: the dose without an observed effect (NOEL) for rats and dogs was 300 mg/kg/day.Conclusion. IPA did not show mutagenic and genotoxic properties in standard in vitro and in vivo tests. With chronic oral administration to rats and dogs, NOEL IPA equal to 300 mg/kg/day provided a systemic exposure that was 8-10 and 41-65 times higher than that in humans, respectively. The results obtained allow us to consider the safety profile of the prolonged use in humans as favorable.
- 14 June 2019
- Published by Morressier GmbH
MYELOSUPPRESSION AND MONITORING OF ABSOLUTE NEUTROPHIL COUNTS IN EPIRUBICIN/CYCLOPHOSPHAMIDE-TREATED BREAST CANCER PATIENTS: RESULTS FROM A PHASE-2A COLLABORATIVE TRIAL OF THE AGO-B AND CESAR STUDY GROUPS
Introduction: Severe neutropenia and infections are frequent adverse events associated with standard chemotherapy regimens. We tightly monitored absolute neutrophil counts (ANCs) in a patient population undergoing anthracycline and cyclophosphamide treatment. Results prompt us to recommend apposite time points to monitor ANCs. Methods: MyeloConcept is a randomized, double-blind,
- 14 June 2019
- Published by Morressier GmbH
MYELOSUPPRESSION AND MONITORING OF ABSOLUTE NEUTROPHIL COUNTS IN EPIRUBICIN/CYCLOPHOSPHAMIDE-TREATED BREAST CANCER PATIENTS: RESULTS FROM A PHASE-2A COLLABORATIVE TRIAL OF THE AGO-B AND CESAR STUDY GROUPS
Introduction: Severe neutropenia and infections are frequent adverse events associated with standard chemotherapy regimens. We tightly monitored absolute neutrophil counts (ANCs) in a patient population undergoing anthracycline and cyclophosphamide treatment. Results prompt us to recommend apposite time points to monitor ANCs. Methods: MyeloConcept is a randomized, double-blind,